Prasugrel
Small molecule targets P2RY12 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | EFFIENT | — | 2013-10-16 – 2016-07-12 | fda.gov ↗ |
| Approved | US (FDA) | EFFIENT | — | 2009-07-10 | fda.gov ↗ |
| Approved | EU (EMA) | Efient | — | 2009-02-24 | europa.eu ↗ |
Trials 120 · started per year
Also used as a comparator or background therapy in 78 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02243137 Background | May 2013 → Jun 2014 | — | David Vivas | Completed | No outcome recorded |
| Phase 1 | NCT01430091 Comparator | Sep → Oct 2011 | sickle cell disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07032389 Background | Dec 2025 → Jun 2030 expected | acute coronary syndrome | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT02507323 Comparator | Feb 2016 → Aug 2017 | cardiovascular disorder | Yochai Birnbaum | Withdrawn | No outcome recorded |
| Phase 2 | NCT01103440 Background | Apr 2007 → Jun 2009 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT07629635 Comparator | Sep 2026 → Dec 2027 expected | migraine disorder, patent foramen ovale | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04445623 Comparator | Jul → Oct 2020 | COVID-19, thrombotic disease | Azienda Ospedaliera Universitaria Integrata Verona | Unknown | No outcome recorded |
| Phase 3 | NCT02866175 Background | Feb 2017 → Jun 2019 | atrial fibrillation | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT01830543 Background | May 2013 → Jul 2016 | atrial fibrillation | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01531114 Comparator | May 2013 → Jul 2015 | ST-elevation myocardial infarction | Gennaro Sardella | Completed | No outcome recorded |
| Phase 3 | NCT01835353 Comparator | Jun 2012 → Jul 2013 | qualitative platelet defect | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT02070159 Comparator | Dec 2011 → Dec 2012 | coronary artery disorder | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT01465828 Comparator | Oct 2011 → Jan 2012 | acute coronary syndrome | Gennaro Sardella | Completed | No outcome recorded |
| Phase 3 | NCT01505790 Comparator | Jul 2011 → May 2012 | acute coronary syndrome | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT01360437 Comparator | May → Dec 2011 | acute coronary syndrome, coronary artery disorder | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT01510327 Background | Oct 2009 → Feb 2010 | coronary artery disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01500434 Background | Feb 2009 → Mar 2011 | coronary artery disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00823212 Background | Jan 2009 → Sep 2010 | coronary atherosclerosis | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 451 trials | ||||||
| Phase 4 | NCT07684742 Comparator | Jul 2026 → Jul 2031 expected | ST-elevation myocardial infarction, acute coronary syndrome, intermediate coronary syndrome | Gyeongsang National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06763744 Comparator | Jun 2025 → Jul 2029 expected | acute coronary syndrome, bleeding disorder, vascular-type | Samsung Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06718179 Background | Nov 2024 → Nov 2029 expected | acute coronary syndrome | Odense University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05709626 Comparator | Feb 2023 → Jan 2025 overdue | ST-elevation myocardial infarction | Kindai University | Recruiting | No outcome recorded |
| Phase 4 | NCT05767723 Comparator | Feb 2023 → May 2025 overdue | acute coronary syndrome | Hospital Israelita Albert Einstein | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05359224 Comparator | Jun 2022 → Jul 2025 | brain aneurysm | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT04609111 Comparator | Jan 2021 → Dec 2023 | acute coronary syndrome | Kyoto University, Graduate School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT04014803 Comparator | Jan 2020 → Jun 2027 expected | coronary artery disorder | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT04006288 Comparator | Sep 2019 → Jan 2022 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT03489863 Comparator | May 2018 → Mar 2019 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT03273075 Comparator | Sep 2017 → May 2021 | acute coronary syndrome, cardiac arrest | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT03027934 Comparator | Aug → Oct 2017 | diabetes mellitus | CirQuest Labs, LLC | Withdrawn | No outcome recorded |
| Phase 4 | NCT02978040 Comparator | Jul 2017 → Aug 2019 | ST-elevation myocardial infarction, coronary artery disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT03062319 Comparator | Apr 2017 → Jul 2023 | atherosclerosis, atrial fibrillation, ischemic stroke | National Hospital Organization Osaka National Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT05247385 Comparator | Mar 2017 → Feb 2021 | coronary artery disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT03016611 Comparator | Feb → Dec 2017 | ST-elevation myocardial infarction, acute coronary syndrome | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02545933 Background | Feb 2016 → May 2019 | myocardial infarction | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT02587260 Comparator | Dec 2015 → Feb 2017 | cardiovascular disorder | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02487732 Comparator | Jul 2015 → Aug 2016 | acute coronary syndrome | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02422888 Comparator | May 2015 → Oct 2017 | myocardial infarction | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 4 | NCT02261922 Comparator | Oct 2014 → Oct 2015 | platelet adenylate cyclase activity | Hotel Dieu de France Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02118870 Comparator | Jun 2014 → Sep 2017 | acute coronary syndrome | Diagram B.V. | Completed | No outcome recorded |
| Phase 4 | NCT02108808 Comparator | Apr → Oct 2014 | — | University of Patras | Completed | No outcome recorded |
| Phase 4 | NCT02065479 Comparator | Mar 2014 → Apr 2019 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT02032303 Comparator | Feb → Dec 2014 | ST-elevation myocardial infarction, acute coronary syndrome, intermediate coronary syndrome | Azienda Policlinico Umberto I | Unknown | No outcome recorded |
| Phase 4 | NCT01869309 Comparator | Jan 2014 → Dec 2015 | coronary artery disorder | LifeBridge Health | Unknown | No outcome recorded |
| Phase 4 | NCT01944800 Comparator | Sep 2013 → Jul 2019 | acute coronary syndrome | German Heart Center Munich | Completed | No outcome recorded |
| Phase 4 | NCT01959451 Comparator | Sep 2013 → May 2016 | acute coronary syndrome | LMU Klinikum | Completed | No outcome recorded |
| Phase 4 | NCT01951001 Comparator | Jul 2013 → Jun 2015 | acute coronary syndrome, hemorrhagic disease, thrombotic disease | Gyeongsang National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02215993 Comparator | Jul 2013 → Sep 2014 | acute coronary syndrome, blood platelet disease | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01789814 Comparator | Jul 2013 → Jul 2014 | coronary artery disorder | Tufts Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02317198 Comparator | Jun 2013 → Nov 2018 | acute coronary syndrome, intermediate coronary syndrome, myocardial infarction | St. Antonius Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01765400 Comparator | May 2013 → Dec 2015 | systolic heart failure | University of Nebraska | Completed | No outcome recorded |
| Phase 4 | NCT02402491 Comparator | Jan 2013 → Jun 2015 | — | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01805570 Comparator | Nov 2012 → Mar 2013 | myocardial infarction | David Antoniucci | Completed | No outcome recorded |
| Phase 4 | NCT01642966 Comparator | Sep 2012 | acute coronary syndrome | University of Patras | Completed | No outcome recorded |
| Phase 4 | NCT01700322 Comparator | Aug 2012 → Jul 2016 | coronary artery disorder | Johannes Gutenberg University Mainz | Completed | No outcome recorded |
| Phase 4 | NCT01642940 Comparator | Jun → Sep 2012 | acute coronary syndrome, coronary artery disorder | University of Patras | Completed | No outcome recorded |
| Phase 4 | NCT01589978 Background | May 2012 → Aug 2014 | coronary artery disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01339026 Comparator | Feb 2012 → Sep 2013 | acute coronary syndrome | Royal Brompton & Harefield NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 4 | NCT01510171 Comparator | Jan → Jun 2012 | ST-elevation myocardial infarction | Careggi Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01463163 Comparator | Oct 2011 → Apr 2012 | qualitative platelet defect | University of Patras | Completed | No outcome recorded |
| Phase 4 | NCT01493999 Comparator | Sep 2011 → Jan 2013 | acute coronary syndrome | University of Pecs | Completed | No outcome recorded |
| Phase 4 | NCT01456364 Comparator | Sep 2011 → Apr 2014 | coronary artery disorder | German Heart Center Munich | Unknown | No outcome recorded |
| Phase 4 | NCT01365221 Comparator | Oct 2010 → Jan 2014 | acute coronary syndrome | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01135667 Comparator | Sep 2010 → Jul 2012 | acute coronary syndrome, coronary artery disorder | Lene Holmvang | Completed | No outcome recorded |
| Phase 4 | NCT01158846 Comparator | Aug 2010 → Jun 2011 | ST-elevation myocardial infarction, strictly posterior acute myocardial infarction | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | Unknown | No outcome recorded |
| Phase 4 | NCT01201772 Comparator | Aug 2010 → May 2011 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00977938 Comparator | Oct 2009 → Jun 2014 | coronary artery disorder | Baim Institute for Clinical Research | Completed | No outcome recorded |
| Phase 4 | NCT00954707 Comparator | Aug 2009 → Jan 2012 | coronary artery disorder | Cordis US Corp. | Unknown | No outcome recorded |
| Phase 4 | NCT01106534 Comparator | Aug 2009 → Feb 2015 | arterial occlusion, coronary restenosis, myocardial ischemia | Abbott Medical Devices | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT04708587 Comparator | Mar 2021 → Mar 2027 expected | chronic kidney disease | Yonsei University | Recruiting | No outcome recorded |
| — | NCT04100135 Background | Feb 2021 → Aug 2024 | migraine disorder, patent foramen ovale | W.L.Gore & Associates | Terminated | No outcome recorded |
| — | NCT03435133 Comparator | Nov 2015 → Oct 2018 | ST-elevation myocardial infarction | AORTICA Group | Completed | No outcome recorded |
| — | NCT02303717 Background | Dec 2014 → Dec 2017 | coronary artery disorder | NHS National Waiting Times Centre Board | Unknown | No outcome recorded |
| — | NCT02016170 Comparator | Mar 2014 → Oct 2015 | acute coronary syndrome, coronary artery disorder | University of Florida | Completed | No outcome recorded |
| — | NCT01852214 Comparator | Feb 2013 → Jul 2015 | coronary artery disorder, type 2 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| — | NCT01852175 Comparator | Jan 2012 → Jun 2014 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| — | NCT01175200 Comparator | Sep 2010 → Jul 2012 | platelet aggregation, spontaneous | Ascopharm Groupe Novasco | Completed | No outcome recorded |
| — | NCT01103843 Comparator | Apr 2010 → Apr 2011 | coronary artery disorder | St. Francis Hospital, New York | Unknown | No outcome recorded |
Press releases naming this drug 33 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-12-15 | Daiichi Sankyo | Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes Related to Additional Indication for the Antiplatelet Agent, Prasugrel Hydrochloride daiichisankyo.com ↗ |
| 2020-07-21 | Daiichi Sankyo | Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients daiichisankyo.com ↗ |
| 2016-10-21 | Daiichi Sankyo | Daiichi Sankyo Announces Phase 3 Clinical Trial (PRASTRO-I Study, PRASTRO-II Study) Results for Prasugrel Antiplatelet Agent for Patients with Ischemic Cerebrovascular Disease daiichisankyo.com ↗ |
| 2016-05-25 | Daiichi Sankyo | Daiichi Sankyo Launches Antiplatelet Agent Efient® Tablets 20mg daiichisankyo.com ↗ |
| 2015-06-01 | Daiichi Sankyo | Daiichi Sankyo Announces Lifting of Prescription Period Limitation for Antiplatelet Agent Efient® 3.75mg/5mg Tablets in Japan daiichisankyo.com ↗ |
| 2014-05-27 | Daiichi Sankyo | Daiichi Sankyo Launches the Antiplatelet Agent Efient® 3.75mg/5mg Tablets daiichisankyo.com ↗ |
| 2014-03-24 | Daiichi Sankyo | Daiichi Sankyo Receives Approval in Japan for Manufacturing and Marketing of the Antiplatelet Agent Efient® 3.75mg/5mg Tablets daiichisankyo.com ↗ |
| 2013-07-12 | Daiichi Sankyo | Daiichi Sankyo Announces Phase 3 Study Results (PRASFIT-Elective Study) for the Antiplatelet Agent Prasugrel in Japan daiichisankyo.com ↗ |
| 2013-06-18 | Daiichi Sankyo | Daiichi Sankyo Submits a New Drug Application in Japan for the Antiplatelet Agent Prasugrel daiichisankyo.com ↗ |
| 2013-03-16 | Daiichi Sankyo | Daiichi Sankyo Announces Positive Phase 3 Study Results (PRASFIT-ACS) for Prasugrel in Japanese Patients with Acute Coronary Syndrome Undergoing PCI daiichisankyo.com ↗ |
| 2013-03-14 | Daiichi Sankyo | Daiichi Sankyo Announces Results of PRASFIT-Elective Study Regarding Use of Prasugrel in Elective Patients with Stable Angina and Chronic Myocardial Infarction Undergoing PCI daiichisankyo.com ↗ |
| 2012-09-21 | Daiichi Sankyo | Daiichi Sankyo Announces PRASFIT-ACS Results Regarding Prasugrel in Acute Coronary Syndrome Patients Undergoing PCI daiichisankyo.com ↗ |
| 2012-08-26 | Daiichi Sankyo | Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient(R) (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure daiichisankyo.com ↗ |
| 2010-06-10 | Daiichi Sankyo | Ranbaxy Launches Antiplatelet Agent Prasugrel in India daiichisankyo.com ↗ |
| 2009-08-06 | Daiichi Sankyo | Effient(TM) is Now Available in Pharmacies daiichisankyo.com ↗ |
| 2009-07-11 | Daiichi Sankyo | Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient™ daiichisankyo.com ↗ |
| 2009-04-08 | Daiichi Sankyo | FIRST LAUNCH OF EFIENT® WORLDWIDE TAKES PLACE IN THE UK daiichisankyo.com ↗ |
| 2009-02-24 | Daiichi Sankyo | European Commission Approves EFIENT®(prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI daiichisankyo.com ↗ |
| 2009-02-04 | Daiichi Sankyo | Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee daiichisankyo.com ↗ |
| 2008-12-19 | Daiichi Sankyo | Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) daiichisankyo.com ↗ |
| 2008-10-17 | Daiichi Sankyo | Daiichi Sankyo and Lilly Respond to Speculation On Status of Prasugrel New Drug Application daiichisankyo.com ↗ |
| 2008-09-27 | Daiichi Sankyo | FDA Continues to Review Prasugrel New Drug Application daiichisankyo.com ↗ |
| 2008-08-25 | Daiichi Sankyo | Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events daiichisankyo.com ↗ |
| 2008-06-24 | Daiichi Sankyo | FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel daiichisankyo.com ↗ |
| 2008-03-31 | Daiichi Sankyo | Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel daiichisankyo.com ↗ |
| 2008-02-22 | Daiichi Sankyo | FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with percutaneous coronary intervention daiichisankyo.com ↗ |
| 2008-02-20 | Daiichi Sankyo | Daiichi Sankyo, Lilly Submit Marketing Authorization Application for Investigational Oral Antiplatelet Drug, Prasugrel, to European Medicines Agency daiichisankyo.com ↗ |
| 2008-01-07 | Daiichi Sankyo | Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration If Approved for Marketing in the United States, Trade Name Will be Effient™ daiichisankyo.com ↗ |
| 2007-11-04 | Daiichi Sankyo | Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel daiichisankyo.com ↗ |
| 2007-11-04 | Daiichi Sankyo | In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack daiichisankyo.com ↗ |
| 2007-10-25 | Daiichi Sankyo | Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies daiichisankyo.com ↗ |
| 2007-01-18 | Daiichi Sankyo | Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to Clopidogrel in Patients with Acute Coronary Syndrome daiichisankyo.com ↗ |
| 2006-10-24 | Daiichi Sankyo | New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses daiichisankyo.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 201 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | prasugrel | “Randomization will be stratified by stent type (cobalt-chromium everolimus-eluting stents, platinum-chromium everolimus-eluting stents, and sirolimus-eluting stents with...” PMID 29447787 ↗ Dec 2017197“A total of 2268 STEMI patients indicated for primary PCI with current generation platinum‑chromium everolimus-eluting stents were randomized 1:1 to either prasugrel monotherapy...” PMID 41436299 ↗ Dec 2025 “Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice...” NCT00823212 ↗ “Every antiplatelet-naïve patient undergoing an elective procedure will be given 300 mg aspirin and loading dose of one of P2Y12 receptor inhibitors (e.g., 600 mg clopidogrel,...” NCT02601157 ↗ “Patients randomized to the antithrombotic monotherapy treatment receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) and...” NCT05955365 ↗ “Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months...” NCT02303717 ↗ “It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets...” NCT02251249 ↗ “Unlike prasugrel and ticagrelor, which are potent P2Y12 inhibitors, clopidogrel is activated in the liver via the cytochrome P450 2C19 (CYP2C19) metabolic pathway to exert its...” NCT06763744 ↗ “Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing...” NCT01852019 ↗ “Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months...” NCT04708587 ↗ “Treatment with clopidogrel 150mg once daily for a minimum of 10 days (max. 14 days), followed by a minimum of 10 days treatment with prasugrel 10mg once daily (max 14 days).” NCT05657041 ↗ “All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.” NCT02402491 ↗ “The polypill will consist of a high-intensity statin (rosuvastatin 40 mg daily), aspirin 81 mg daily, and either clopidogrel 75 mg or prasugrel 10 mg daily.” NCT05514938 ↗ “Subjects must be treated with one of the following P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) for 3 months following the index procedure.” NCT02605447 ↗ “The polypill combines DAPT and a high intensity statin: (a) aspirin 81 mg, (b) rosuvastatin (40 or 10 mg) and (c) prasugrel 10 mg or clopidogrel 75 mg.” NCT07032389 ↗ “clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure).” NCT01510327 ↗ “* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)” NCT01589978 ↗ “Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI.” NCT01103843 ↗ “Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years.” NCT05650411 ↗ “Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.” NCT05773989 ↗ “DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.” NCT03606642 ↗ “potent P2Y12 inhibitor monotherapy will be administered as prasugrel 10 mg once daily or ticagrelor 90 mg twice daily.” NCT07684742 ↗ “The other group discontinued antiplatelets (i.e. clopidogrel, ticagrelor, prasugrel) for 7 days before colonoscopy.” NCT02865824 ↗ “Prasugrel (10 mg/day) or Ticagrelor (180 mg/day) are strongly recommended as compared to Clopidogrel (75 mg/day)).” NCT02118870 ↗ “Subjects randomized to the Monotherapy Group will be treated with ticagrelor or prasugrel alone for 12 months.” NCT04360720 ↗ “This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner.” NCT01869309 ↗ “1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)” NCT05066789 ↗ “when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used” NCT01212302 ↗ “prasugrel (outside the United States and if approved at the time of the procedure)” NCT01500434 ↗ “doses of clopidogrel (n = 94), prasugrel (n = 43) or ticagrelor, (n = 143).” PMID 34143384 ↗ Jun 2021 “DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month.” NCT05952206 ↗ “Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)” NCT01069003 ↗ “1-month prasugrel monotherapy followed by clopidogrel monotherapy” NCT04609111 ↗ “aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol” NCT03062319 ↗ “Free choice among clopidogrel, prasugrel or ticagrelor” NCT01477775 ↗ “Prasugrel: If patient is aged less than 75 years” NCT02735707 ↗ “DAPT with prasugrel (or ticagrelor) and ASA” NCT05262803 ↗ “50 patients treated with prasugrel 5mg” NCT05903976 ↗ “Ticagrelor","Prasugrel","Clopidogrel” NCT04505774 ↗ “Prasugrel plus Aspirin arm” NCT04014803 ↗ “Drug: Prasugrel” NCT02065479 ↗ “Drug: Prasugrel” NCT03027934 ↗ “Prasugrel” NCT01103440 ↗ |
| Known as | Effient | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗ |
| Known as | EFFIENT (prasugrel) | “EFFIENT (prasugrel)” NCT01589978 ↗ |
| Known as | Efient | “It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets...” NCT02251249 ↗1“Group 2: Prasugrel (Efient)” NCT01339026 ↗ |
| Known as | Generic name: Prasugrel | “Generic name: Prasugrel” NCT01099566 ↗ |
| Known as | LY-640315 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗ |
| Known as | NSC-759625 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗ |
| Known as | Prasu doc | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗ |
| Known as | Prasugrel (Effient) | “Prasugrel (Effient)” NCT01184300 ↗ |
| Known as | Prasugrel = EFIENT | “Prasugrel = EFIENT” NCT01493999 ↗ |
| Known as | PRASUGREL BESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗ |
| Known as | Prasugrel hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗ |
| Known as | Prasugrel Hydrochloride | “Prasugrel Hydrochloride 10 MG Oral Tablet” NCT04445623 ↗ |
| Known as | Prasugrel viatris (previously prasugrel mylan) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗ |
| Action | Inhibit | “maintaining high levels of inhibition of platelet aggregation via P2Y(12) receptor inhibition” PMID 18498956 ↗ May 2008 |
| Modality | Small molecule | “Prasugrel, a new thienopyridine” PMID 17982182 ↗ Nov 2007 |
| Route | Oral | “Administered orally” NCT00059215 ↗ |
| Target | P2RY12 | “Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class...” NCT02016170 ↗ |